Tags : P-III

Biosimilars Clinical Trials

STADA and Xbrane’s Xlucane (biosimilar, ranibizumab) Meet its Primary Endpoint

Shots: The P-III Xplore study involves assessing ranibizumab biosimilar vs Lucentis in 583 patients. The study met its 1EPs demonstrating the equivalent efficacy in BCVA @ 8wks. treatment Additionally, the interim analysis of 6mos. data demonstrated that the biosimilar has a similar PK, safety, and immunogenicity profile compared to Lucentis. The companies plan to submit […]Read More